Poster
Improving the safety pharmacology standard: CNS behavioural investigations using anticholinergics as a comparator against the standard Irwin test
September 22, 2024
SPS 2024 -- The ICH S7A safety pharmacology guidelines require a novel test article to be assessed for central nervous system (CNS) effects as a part of the core battery. Although follow-up behavioral studies are advised, these are rarely seen as part of the GLP safety pharmacology package of work, with an Irwin screen alone conducted to address this requirement. Anticholinergics are a type of drug that block acetylcholine (Ach), a neurotransmitter at synapses in the central and peripheral nervous system.
